Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and Drug-Gene Interaction Network

The study analyzed data from the Food and Drug Administration Adverse Event Reporting System (FAERS) from 2004 to 2018 to investigate the association between montelukast, a medication for asthma and allergies, and neuropsychiatric adverse events (AEs). The analysis revealed high reporting odds ratios for suicidal ideation (21.5) and depression (8.2) linked to montelukast. Researchers identified 1,144 human genes interacting with montelukast, with functional enrichment analysis highlighting significant involvement in "neuroactive ligand–receptor interaction" and associations with "mood disorders" and "major depressive disorder." The findings suggested a significant link between montelukast and neuropsychiatric AEs, indicating the need for further research into the drug's pharmacological mechanisms.